Compare PRME & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRME | CAPR |
|---|---|---|
| Founded | 2019 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 526.0M | 584.9M |
| IPO Year | 2022 | 2011 |
| Metric | PRME | CAPR |
|---|---|---|
| Price | $4.23 | $8.36 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 13 | 10 |
| Target Price | $7.03 | ★ $27.25 |
| AVG Volume (30 Days) | ★ 5.5M | 3.6M |
| Earning Date | 11-12-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 18.18 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,632,000.00 | N/A |
| Revenue This Year | $18.58 | N/A |
| Revenue Next Year | $23.34 | $85.77 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 55.28 | N/A |
| 52 Week Low | $2.67 | $2.96 |
| 52 Week High | $5.91 | $40.37 |
| Indicator | PRME | CAPR |
|---|---|---|
| Relative Strength Index (RSI) | 51.32 | 50.24 |
| Support Level | $2.94 | $7.78 |
| Resistance Level | $4.80 | $10.42 |
| Average True Range (ATR) | 0.53 | 1.01 |
| MACD | -0.08 | 0.23 |
| Stochastic Oscillator | 22.25 | 45.99 |
Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.